LUIS ALBERTO
MENCHÉN VISO
Profesor asociado de Ciencias de la Salud
CARLOS
TAXONERA SAMSO
Profesor asociado de Ciencias de la Salud
Publicaciones en las que colabora con CARLOS TAXONERA SAMSO (9)
2022
-
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: the Practicrohn study
Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 8, pp. 807-813
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2015
-
Incidence, management, and course of cancer in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 9, Núm. 4, pp. 326-333
2008
-
Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis
Alimentary Pharmacology and Therapeutics, Vol. 28, Núm. 5, pp. 623-628
-
Open-label infliximab therapy in Crohn's disease: A long-term multicenter study of efficacy, safety and predictors of response
Gastroenterologia y Hepatologia, Vol. 31, Núm. 7, pp. 421-426